Jordan Picks Up Two International Honors
PHILADELPHIA (December 6, 2005) -- V. Craig Jordan, OBE, PhD, DSc, vice president and scientific director for the medical science division at Fox Chase Cancer Center and holder of the Alfred G. Knudson Jr., MD, PhD, Chair in Cancer Research, has received an honorary doctorate and an honorary professorship from two prestigious institutions.
In November, Jordan was awarded an honorary Doctor of Science degree from the University of Bradford, U.K. Also, he was elected honorary Professor at the University of Iguacu, Rio de Janeiro, Brazil.
Both honored his scientific contribution to the development of tamoxifen and raloxifene. Jordan's published studies of tamoxifen and other selective estrogen-receptor modulators-called "designer estrogens"-have made him one of the top 20 most-cited breast cancer researchers over the past decade.
Jordan has been studying the effects of tamoxifen for his entire career. He was the first scientist to focus attention on tamoxifen's anticancer properties and its ability to prevent breast cancer in laboratory mice. His pioneering work guided the evolution from preclinical lab studies to clinical research on the drug, which for the past 30 years has been an established treatment both for advanced breast cancer and as follow-up, or adjuvant, treatment to prevent patients from developing a cancer in the second breast. More recently, he has been involved in developing a second estrogen-modulating compound, the osteoporosis drug raloxifene, now being tested as a preventive agent for breast cancer.
Jordan's long list of national and international awards includes the General Motors Cancer Research Foundation's 2003 Charles F. Kettering Prize for the most outstanding contribution to cancer treatment, the American Cancer Society's 2002 Medal of Honor for basic research, the 2001 Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research and the first Brinker International Breast Cancer Award for Basic Science from the Susan G. Komen Foundation in 1992. In 2002, Queen Elizabeth II named him an Officer of the Most Excellent Order of the British Empire (OBE) for services to international breast cancer research.
In addition, Jordan has been honored by the American Association for Cancer Research, in 1989 and 2002, the British Pharmacological Society, the American Society for Pharmacology and Experimental Therapeutics, the Royal Society of Chemistry and many other professional groups and institutions around the world. He also received the Pennsylvania Breast Cancer Coalition's 2001 Pink Ribbon Award for outstanding individuals dedicated to finding a cure for breast cancer.
Before joining Fox Chase, Jordan was the Diana, Princess of Wales Professor of Cancer Research, professor of cancer pharmacology and director of the Lynn Sage Breast Cancer Research Program at the Robert H. Lurie Comprehensive Cancer Center at Northwestern. He was also professor of molecular pharmacology and biological chemistry and professor of medicine at Northwestern's Feinberg School of Medicine.
Born in Texas to an English mother and American father, he grew up in rural England and earned his undergraduate and doctoral degrees in pharmacology at the University of Leeds, completing his Ph.D. in 1972. Although appointed to the faculty at Leeds, Jordan first came to the United States for postdoctoral training. He was a research associate and then a visiting scientist at the Worcester Foundation for Experimental Biology in Shrewsbury, Mass., from 1972 to 1973.
After teaching at Leeds until 1979, he held a one-year appointment at the endocrinology unit at the Ludwig Institute for Cancer Research at the University of Berne in Switzerland and then joined the University of Wisconsin faculty in 1980. For his seminal contributions to the pharmacology of non-steroidal anti-estrogens, Leeds awarded him a doctor of science degree in 1985 and he became a full professor of human oncology and pharmacology at Wisconsin the same year. His roles at Wisconsin included directing the University of Wisconsin Comprehensive Cancer Center Breast Cancer Program until he joined the Northwestern faculty in 1993.
Fox Chase Cancer Center, part of Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase also was among the first institutions to receive the National Cancer Institute’s prestigious comprehensive cancer center designation in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are routinely recognized in national rankings, and the Center’s nursing program has achieved Magnet status for excellence three consecutive times. Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research and oversees programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX-CHASE (1-888-369-2427).